India · Delayed Price · Currency is INR Aarti Pharmalabs Earnings Call Transcripts
Fiscal Year 2027
-
Standalone Q1 FY27 revenue rose 42% YoY to ₹535 crore and PAT increased 49% to ₹71 crore. FY27 guidance includes 22%–25% standalone EBITDA margin and 40%–50% CDMO/CMO growth, weighted to H2.
Fiscal Year 2026
-
FY26 revenue rose to INR 1,798 crore, while EBITDA and PAT declined amid forex and cost pressures. Record CDMO and Xanthine sales, capacity ramp-ups and 15%-18% long-term growth guidance frame the outlook.
-
Q3 revenue and PAT declined YoY, while EBITDA was nearly flat. Atali start-up delays and softer APIs temper FY26 growth, with CDMO and xanthine capacity expected to support future expansion.
-
Q2 consolidated revenue and EBITDA declined YoY, with API mix pressure and forex loss weighing on earnings. FY26 standalone EBITDA growth guidance is 8%-12%, while CDMO/CMO growth is expected to exceed 30%-40%.
-
Standalone EBITDA rose 14% YoY and PAT 9% despite lower revenue; consolidated comparisons reflect Ganesh Polychem’s move to equity-method accounting. FY26 growth plans rely on CDMO momentum and H2 capacity additions.
-
Q3 delivered record profit, with consolidated revenue up 20% and EBITDA up 34% YoY. Growth spans all three segments; management expects FY25 EBITDA growth to exceed prior guidance and sees significant CDMO/CMO potential, alongside capacity additions and temporary Vapi shipment delays.
Fiscal Year 2025
-
FY 2025 delivered record EBITDA and PAT, with revenue up 14% and all three segments contributing to growth. FY 2026 guidance calls for 12%-15% standalone EBITDA growth and 30%-40% CDMO/CMO revenue growth, alongside heavy capacity investment.
-
H1 FY25 revenue rose 13% to INR 1,014 crore, with EBITDA up 13% to INR 197 crore. FY25 EBITDA growth guidance was reaffirmed, while CDMO timing and Chinese price pressure remain key uncertainties.
-
Q1 FY25 revenue rose 21% YoY and PAT rose 18%, while lower CDMO/CMO mix pressured standalone gross margin. CDMO pipeline expanded to 53 projects, with 25%-30% FY25 growth guidance maintained.
Fiscal Year 2024
-
Q4 FY24 set records for consolidated EBITDA and PAT, with FY EBITDA up 13% and PAT up 12%. FY25 brings ₹550-600 crore of planned capex, while growth depends on CDMO/CMO expansion, new capacity and volatile pharma markets.
-
Q3 FY24 posted record EBITDA of INR 97 crore and PAT of INR 53 crore. CDMO/CMO growth and exports supported margins, while API and xanthine pricing pressure persists; FY24 EBITDA growth guidance is 8%-10%.